Patients with WHO grade II and III gliomas and secondary GBM (WHO Grade IV) frequently harbor IDH mutations; However, the IDH mutation rate in patients with primary GBM (WHO Grade IV) is low [6, 16–18]. The gene discussed is IDH2; the disease is central nervous system cancer.